FeatureName:distant_metastasis_pathologic_spread|Type:BIN|StatisticMethod:ranktest|GroupComparison:m0/m1|Statistics:715.000000|Direction: 1|PValue:0.000562255|FDR:0.0612282;FeatureName:preoperative_pretreatment_cea_level|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics: -0.293662|Direction:-1|PValue:0.019493468|FDR:0.7329800;FeatureName:residual_tumor|Type:CAT|StatisticMethod:kruskal|GroupComparison:r0/r2/rx/r1|Statistics: 11.298578|Direction: 1|PValue:0.010216208|FDR:0.1602295;FeatureName:tumor_stage|Type:CAT|StatisticMethod:kruskal|GroupComparison:stage ii/stage i/stage iii/stage iv|Statistics: 11.998460|Direction: 1|PValue:0.007388436|FDR:0.1278052;FeatureName:MSI_status_TCGAPaper_threegroup|Type:CAT|StatisticMethod:kruskal|GroupComparison:MSS/MSI-L/MSI-H|Statistics:  6.181163|Direction: 1|PValue:0.045475495|FDR:0.1297261;FeatureName:MSI_status_TCGAPaper_twogroup|Type:BIN|StatisticMethod:ranktest|GroupComparison:MSS/MSI|Statistics:421.000000|Direction:-1|PValue:0.012370070|FDR:0.0687776;FeatureName:MLH1_silencing|Type:BIN|StatisticMethod:ranktest|GroupComparison:0/1|Statistics:230.000000|Direction:-1|PValue:0.018377003|FDR:0.0946075;FeatureName:hypermutated|Type:BIN|StatisticMethod:ranktest|GroupComparison:0/1|Statistics:265.000000|Direction:-1|PValue:0.007397574|FDR:0.0311595;FeatureName:silent_mutrate|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics:  0.297226|Direction: 1|PValue:0.011228932|FDR:0.0459065;FeatureName:nonsilent_mutrate|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics:  0.268605|Direction: 1|PValue:0.022524948|FDR:0.0846207;FeatureName:CUBN_mutation|Type:BIN|StatisticMethod:ranktest|GroupComparison:0/1|Statistics:328.000000|Direction:-1|PValue:0.045890126|FDR:0.1876096;FeatureName:RYR2_mutation|Type:BIN|StatisticMethod:ranktest|GroupComparison:0/1|Statistics:404.000000|Direction:-1|PValue:0.032748814|FDR:0.3285745;FeatureName:MUC16_mutation|Type:BIN|StatisticMethod:ranktest|GroupComparison:0/1|Statistics:424.000000|Direction:-1|PValue:0.032672836|FDR:0.1135381;FeatureName:HYDIN_mutation|Type:BIN|StatisticMethod:ranktest|GroupComparison:0/1|Statistics:276.000000|Direction:-1|PValue:0.041522864|FDR:0.3037725;FeatureName:20q11.21_Amplification|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics: -0.260463|Direction:-1|PValue:0.014250676|FDR:0.0428135;FeatureName:20q12_Amplification|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics: -0.232763|Direction:-1|PValue:0.029082927|FDR:0.0763562;FeatureName:8q24.21_Amplification|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics: -0.223009|Direction:-1|PValue:0.036754944|FDR:0.5618703;FeatureName:20q13.31_Amplification|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics: -0.272587|Direction:-1|PValue:0.010187899|FDR:0.0314693;FeatureName:16p11.2_Amplification|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics: -0.263543|Direction:-1|PValue:0.013103951|FDR:0.0404766;FeatureName:10q22.3_Amplification|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics:  0.258901|Direction: 1|PValue:0.014864394|FDR:0.5527197;FeatureName:1p33_Deletion|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics:  0.230536|Direction: 1|PValue:0.030703592|FDR:0.2906047;FeatureName:10q21.1_Deletion|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics:  0.223237|Direction: 1|PValue:0.036557848|FDR:0.5493752;FeatureName:10q23.31_Deletion|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics:  0.242600|Direction: 1|PValue:0.022762987|FDR:0.5380380;FeatureName:7q31.1_Deletion|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics: -0.369301|Direction:-1|PValue:0.000398841|FDR:0.0171589;FeatureName:18p11.31_Deletion|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics:  0.273981|Direction: 1|PValue:0.009793091|FDR:0.0351666;FeatureName:1p13.2_Deletion|Type:CON|StatisticMethod:spearman|GroupComparison:|Statistics:  0.214881|Direction: 1|PValue:0.044379639|FDR:0.2284730